Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06910072 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）(UPGRADE-TNBC) | enrolling by invitation | Phase 2 / Phase 3 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06680596 | Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy(SAFIR3LibHERty) | enrolling by invitation | Phase 2 | 80 | UNICANCER |
| 1 |
| Aug 3, 2026 |
| clinicaltrials |
| NCT07275463 | [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression | enrolling by invitation | Phase 2 | 40 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07292571 | Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 | enrolling by invitation | Phase 2 | 50 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06650748 | Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer(NeoMARS) | enrolling by invitation | Phase 2 | 100 | Peking UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07376629 | A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC | enrolling by invitation | Phase 2 | 60 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07359404 | Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC | enrolling by invitation | Phase 2 | 60 | YING FANOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06843681 | Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study | enrolling by invitation | Phase 2 | 54 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06958445 | Prevention of Oral Mucositis and Improvement of Quality of Life for Patients With Breast Cancer Undergoing Adjuvant Radiotherapy(SAFE) | enrolling by invitation | Phase 2 | 90 | Taipei City HospitalOTHER_GOV | 1 | May 6, 2025 | clinicaltrials |
| NCT06768268 | A Dose-Image Optimization Trial Evaluating Mannitol and Voluven as Adjuncts for Indocyanine Green(ICGMV) | enrolling by invitation | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06890871 | Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study | enrolling by invitation | Phase 1 / Phase 2 | 25 | Zhongnan HospitalOTHER | 1 | Mar 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2026source: clinicaltrials